Kura Oncology Balance Sheet
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kura Oncology financial position
At the end of fiscal 2025, Kura Oncology reported total assets of $738.4 million, down 2.9% from a year earlier against total liabilities of $564.2 million. Shareholders' equity stood at $174.1 million, or 23.6% of assets. The company held $149.1 million in cash and equivalents against $9.7 million of debt, a net cash position of $139.4 million.
The current ratio (current assets divided by current liabilities) was 6.06, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.06.
Summary generated from market data by MetaCap's automated system. Methodology
Kura Oncology balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 149.10M | 224.46M | 37.32M | 51.80M | 90.67M | 325.49M | 26.14M | 16.12M | 11.43M | 9.72M |
| Short-Term Investments | 518.14M | 502.93M | 386.64M | 386.18M | 427.29M | 307.83M | 210.76M | 162.87M | 81.71M | 58.06M |
| Receivables | 8.80M | 2.06M | — | — | — | — | — | — | — | — |
| Inventory | 413.00K | 0 | — | — | — | — | — | — | — | — |
| Total Current Assets | 708.66M | 744.83M | 432.48M | 446.43M | 522.29M | 637.29M | 239.60M | 181.20M | 94.64M | 68.81M |
| Property, Plant & Equipment | 7.86M | 1.68M | 1.86M | 2.54M | 2.67M | 2.02M | 44.00K | — | 10.00K | 40.00K |
| Total Assets | 738.36M | 760.16M | 448.94M | 456.31M | 534.05M | 647.21M | 241.97M | 182.38M | 95.85M | 69.82M |
| Accounts Payable | 5.02M | 1.47M | 2.30M | 1.53M | 3.24M | 2.75M | 3.53M | 3.94M | 1.25M | 638.00K |
| Short-Term Debt | 0 | 2.61M | — | — | — | 3.00M | 250.00K | — | 1.53M | — |
| Total Current Liabilities | 116.97M | 78.71M | 35.26M | 24.06M | 22.45M | 26.02M | 15.56M | 13.62M | 10.03M | 5.45M |
| Long-Term Debt | 9.71M | 6.92M | 9.33M | 9.16M | — | 4.25M | 7.25M | 7.50M | 5.57M | 7.32M |
| Total Liabilities | 564.23M | 346.52M | 51.66M | 36.03M | 27.44M | 36.31M | 23.19M | 21.39M | 15.99M | 12.95M |
| Shareholders' Equity | 174.13M | 413.64M | 397.27M | 420.28M | 506.61M | 610.90M | 218.78M | 160.99M | 79.86M | 56.88M |
| Retained Earnings | -1.17B | -895.42M | -721.44M | -568.81M | -432.97M | -302.50M | -212.88M | -149.74M | -89.29M | -53.86M |
| Total Debt | 9.71M | 9.52M | 9.33M | 9.16M | — | 7.25M | 7.50M | 7.50M | 7.10M | 7.32M |
| Net Cash (Debt) | 657.53M | 717.87M | 414.63M | 428.83M | 517.96M | 626.07M | 229.39M | 171.49M | 86.05M | 60.47M |
| Shares Outstanding | 87.86M | 78.23M | 74.35M | 68.31M | 66.57M | 66.19M | 45.38M | 38.15M | 29.42M | 19.35M |
This table shows 10 annual periods of Kura Oncology's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KURA's reporting calendar. What is a balance sheet?